Profil bibliographique

Michael Jeserich

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

59Publications signalées

4160Citations signalées

0Affiliations récentes

Domaines associés

Cardiac Imaging and DiagnosticsViral Infections and Immunology ResearchLipoproteins and Cardiovascular HealthPericarditis and Cardiac TamponadeCardiovascular Effects of Exercise

Publications récentes

Accès ouvert 2025 articleOpenAlex

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler, Ciaran J. McMullan et autres

44 citationsThe Lancet

Accès ouvert 2025 articleOpenAlex

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom, Irina Barash et autres

81 citationsThe Lancet

Accès ouvert 2025 articleOpenAlex

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Philippe Gabríel Steg, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt et autres

25 citationsCirculation

Accès ouvert 2024 articleOpenAlex

Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study

Kausik K. Ray, Carlos Aguíar, Marcello Arca, Derek Connolly et autres

76 citationsEuropean Journal of Preventive Cardiology

2024 articleOpenAlex

Patient knowledge about risk factors, achievement of target values, and guideline-adherent secondary prevention therapies 12 months after acute myocardial infarction

Uwe Zeymer, Franz Goss, Marcel Kunadt, S.J. Oldenburg et autres

6 citationsEuropean Heart Journal Acute Cardiovascular Care

2024 articleOpenAlex

Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry

Guillaume Roger, Grégory Ducrocq, Jules Mesnier, Neila Sayah et autres

11 citationsEuropean Heart Journal

Accès ouvert 2024 articleOpenAlex

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

24 citationsEuropean Heart Journal - Cardiovascular Pharmacotherapy

Accès ouvert 2022 articleOpenAlex

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

125 citationsCirculation

Accès ouvert 2021 articleOpenAlex

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction

Burkert Pieske, Rolf Wachter, Sanjiv J. Shah, Abigail S. Baldridge et autres

167 citationsJAMA

Accès ouvert 2021 articleOpenAlex

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Manvelian et autres

144 citationsJournal of the American College of Cardiology

Accès ouvert 2021 articleOpenAlex

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner, Deepak L. Bhatt et autres

40 citationsDiabetes Care

Accès ouvert 2020 articleOpenAlex

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Carolyn S.P. Lam, Anna Giczewska, Karen Sliwa, Frank Edelmann et autres

84 citationsJAMA Cardiology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.